Notably, genes with higher expression levels in the bone metastatic tumors demonstrated a pro-angiogenic signature, and were enriched in blood vessel development and VEGFA-VEGFR2 signaling pathways (Fig. 2a, b and Supplementary Fig. 3a, b), suggesting the angiogenesis ability of cancer cells in the BMRCC. The gene discussed is VEGFA; the disease is cancer.